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Abstract
Objective: Cardiac surgery with cardiopulmonary bypass (CPB) results in expression of cytokines and adhesion molecules (AM) with
subsequent in¯ammatory response. The purpose of the study was to evaluate the clinical impact of modi®ed ultra®ltration (MUF) and its
ef®cacy in reducing cytokines and AM following coronary artery bypass grafting (CABG) in adults. Methods: A prospective randomized
study of 97 patients undergoing elective CABG was designed. Fifty patients were operated on using normothermic and 47 patients using
hypothermic CPB. The normothermic group was subdivided into a group with modi®ed ultra®ltration (n  30) and a group without MUF
(n  20). In the hypothermic group 30 patients received MUF compared to 17 patients serving as controls. MUF was instituted after CPB for
15 min through the arterial and venous bypass circuit lines. Cytokines (IL-6, IL-8, TNF-a , IL-2R) and adhesion molecules (sE-selectin,
sICAM-1) were measured preoperatively, pre-MUF, in the ultra®ltrate, 24 h, 48 h and 6 days after surgery by chemiluminescent enzyme
immunometric assay or enzyme-linked immunosorbent assay (ELISA). Clinical parameters were collected prospectively until discharge.
Results: In all patients AM and cytokines were signi®cantly elevated after normothermic and hypothemic CPB. AM and cytokines were
signi®cantly higher in hypothermia compared to normothermia. In hypothermic CPB sE-selectin was decreased after 24 h by 37%
(P , 0:0063) and by 40% (P , 0:0027) after 48 h postoperatively. ICAM-1 was reduced by 43% (P , 0:0001) after 24 h and by 60%
(P , 0:0001) after 6 days. Similar results were seen in cytokines with reduction up to 60% after 24 h. Changes after 48 h were noticeable but
not signi®cant. Reduction of AM and cytokines after normothermic CPB was minimal. Neither in normothermia, nor in hypothermia has sIL-
2R been effectively removed from the circulation. There were no signi®cant differences in the clinical variables between the patients with or
without MUF. Conclusion: AM and cytokines are signi®cantly elevated after hypothermic CPB compared to normothermic CPB. MUF led
to a signi®cant reduction in cytokine and AM levels after hypothermic CPB, except for IL-2R. MUF showed minimal effect in normothermia.
We conclude that MUF is an ef®cient way to remove cytokines and AM. However, we were unable to demonstrate any signi®cant impact of
MUF in outcome of adults after elective CABG. q 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The systemic in¯ammatory response that occurs in
humans after cardiopulmonary bypass (CPB) remains a
major cause of morbidity and mortality. The most evident
part in the whole-body in¯ammatory response is the
systemic endothelial cell±neutrophil adhesion that results
from the release of complement degradation products and
cytokines after blood exposure to the arti®cial conduits of
the cardiopulmonary circuits [1]. The systemic in¯amma-
tory response may have a particularly deleterious effect on
the heart where an additional insult occurs from myocardial
ischemia during cardiac arrest [2]. Myocardial ischemia,
present in many patients preoperatively and as a result of
cardioplegic arrest during cardiopulmonary bypass, acti-
vates the vascular endothelium to recruit neutrophils that
accentuate injury upon reperfusion with oxygenated blood
[3].
The cellular and molecular mechanisms of neutrophil±
endothelial cell adhesion in ischemia/reperfusion injury
are increasingly understood. Shreeniwas et al. [4] and
ZuÈnd et al. [5] demonstrated the induction of adhesion
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molecules (E-selectin, ICAM-1) on the surface of endothe-
lial cells rendered hypoxic and being injured when these
cells are reoxygenated, emphasizing the importance of
reperfusion in this syndrome. In addition, postoperative
episodes of myocardial ischemia were signi®cantly corre-
lated with peak elevations of cytokines (TNF-a , IL-1, IL-6,
IL-8) which are responsible for direct cell damage as well as
increased activation of neutrophils.
The technique of modi®ed ultra®ltration has been
claimed to reduce the serum level of in¯ammatory media-
tors generated during CPB and to improve myocardial post-
operative function as well as postoperative convalescence in
infants and children [6]. The purpose of this prospective
randomized study is to evaluate the ef®cacy of modi®ed
ultra®ltration in adults to reduce the plasma levels of cyto-
kines and adhesion molecules as well as clinical outcome in
elective cardiac surgery with cardiopulmonary bypass.
2. Material and methods
2.1. Patient groups
After approval of the Ethics committee for Surgery and
Anesthesia at the University Hospital ZuÈrich 97 patients
were recruited for this study undergoing elective coronary
artery bypass grafting using normothermic (378C) or
hypothermic (26±288C) cardiopulmonary bypass. Between
July 1997 and May 1999 we enrolled 50 patients with
normothermic CPB (mean age 62.1 years) and 47 patients
with hypothermic CPB (mean age 58.7 years). Both groups
were subdivided into a group with modi®ed ultra®ltration
(n  30) and a group without modi®ed ultra®ltration
(n  20 and n  17). Patients with diabetes, preoperative
ischemia or previous coronary artery bypass surgery were
excluded from the study. Cardiopulmonary bypass time in
the normothermia group was mean 77 ^ 17 min (46 ^ 15
min of cardiac arrest time). In the hypothermia group cardi-
opulmonary bypass time was 98 ^ 23 and 60 ^ 20 min of
cardiac arrest time. Within the two groups there were no
signi®cant differences in cardiopulmonary bypass time as
well as in cardiac arrest time. Informed consent was
obtained from each patient according to the protocol of
the Ethics committee of the University Hospital of ZuÈrich.
2.2. Operative techniques
Cardiopulmonary bypass was performed with a StoÈckert
roller pump system (StoÈckert Instrumente GmbH, Munich,
Germany) and a Shiley-Dideco Maxima hollow ®ber oxyge-
nator (Dideco, Mirandola, Italy). Myocardial protection was
accomplished using Buckberg cardioplegia with an initial
dose of 15 ml/kg. Infusions of 300 ml were repeated every
20 min or earlier if electrical activity returned. Before aortic
declamping 500 ml warm blood cardioplegia was adminis-
tered at 378C for 2 min at a pressure of 50 mmHg. The
operations were performed under normothermic by one
surgeon (M.T.) and under hypothermic conditions by three
different surgeons according to the usual practice of our
clinic. Rewarming was achieved using the heat-exchange
oxygenator, warming blanket, and heated humidi®ed gases
to reach a rectal temperature of .348C before terminating
CPB.
2.3. Modi®ed ultra®ltration
After completion of CPB an ultra®ltration modi®ed in
1991 by Elliott and coworkers [7] was performed in hepar-
inized patients between the arterial and the venous tubings
of the CPB circuit, using a Gambro FH22 ®lter with an
effective membrane are of 0.2 m2 and a pore size of 5 nm
(Gambro Dialysatoren GmbH and Co. KG, Hechingen,
Germany). In general, if the molecular weight is between
0 and 8 kDa, all molecules are removed, no matter what
their structure is. Between 8 and 40 kDa not all molecules
are removed, only those with a certain con®guration. The
blood ¯ow through the ®lter was about 200 ml/min, which
was maintained by a roller pump on the inlet part of the
®lter. Suction was applied to the ®ltrate port to achieve an
ultra®ltration rate of 100±150 ml/min. The process was
carried out until an ultra®ltration volume of 50% of the
net CPB-volume balance has been achieved.
2.4. Blood sampling
Blood samples (10 ml) required for determination of IL-
6, IL-8, IL-2R, TNF-a , sE-selectin, and sICAM-1 were
obtained form a venous line of the patient at the following
times: preoperatively after induction of anesthesia, before
instituting modi®ed ultra®ltration, the ultra®ltrate itself,
after modi®ed ultra®ltration, 24 h, 48 h, and 6 days post-
operatively. Blood samples were allowed to coagulate,
centrifuged for 20 min at 48C with 4000 U/min and the
serum was aliquoted and stored at 2708C and analyzed
within a tolerable time frame. Soluble adhesion molecules
in the serum were measured using commercially available
ELISA kits (R&D Systems, Abingdon, UK). Standards of
known concentration were run in parallel together with a
control serum. The optical density (OD) was read at 450 nm
with a correction wavelength set to 630 nm. The absorbency
was plotted against a standard curve of known concentra-
tions and expressed as nanograms per milliliter. The values
were corrected by hemodilution using the hematocrit.
Cytokines (TNF-a , IL-6, IL-8, IL-2R) were analyzed by
the technique of a solid-phase, two-site chemiluminescent
enzyme immunometric assay (Immulite, Euro/DPC Ltd.,
Gwynedd, UK).
2.5. Clinical variables
Patient demographic data and medical history were
collected prospectively, as well as the postoperative course
including intubation time (h), blood loss in 24 h (ml), given
transfusion (ml), alveolar-arterial oxygen gradient (PAaO2),
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inotropic requirement, pulmonary infection requiring anti-
biotic treatment, atrial ®brillation, body temperature (max,
min), ICU stay (days), leukocytes count and CRP for 6 days
(min, max), length of hospital stay (days).
2.6. Statistics
Data were processed with Statview software (Abacus
Concepts Inc., Berkeley, CA). All data were expressed as
mean with one standard deviation and were graphically
presented as bar charts. Intergroup comparison was
performed with the Mann±Whitney test for unpaired data.
Intragroup comparison was done using the Wilcoxon test for
paired data. Differences between groups at speci®c time
intervals were inspected by repeated-measures analysis
with multivariate analysis of variance, as well as correlation
analysis (SPSS Software Inc., Chicago, IL). P-values ,0.05
were considered statistically signi®cant.
3. Results
In all patients sICAM-1, sE-selectin, IL-6, IL-8, IL-2R, as
well as TNF-a were signi®cantly elevated postoperatively
after normothermic and hypothermic CPB compared to
preoperative levels.
3.1. Modi®ed ultra®ltration (MUF) in hypothermic CPB
Adhesion molecules after hypothermic CPB were signif-
icantly lowered by MUF. Soluble E-selectin was decreased
by 37% 24 h postoperatively from mean 302:1 ^ 123:9 to
191:7 ^ 184:4 ng/ml (P , 0:0063), by 40% 48 h postopera-
tively from mean 241:8 ^ 98:9 to 150:3 ^ 137:9 ng/ml
(P , 0:0027). After 6 days sE-selectin levels were almost
reduced to baseline from mean 146:2 ^ 62:5 to 98 ^ 73:5
ng/ml (P , 0:0084).
Soluble ICAM-1 showed similar changes after 24 h with a
reduction of 43% from mean 575:9 ^ 212:9 to 333:5 ^
143:8 ng/ml (P , 0:0001), by 44% after 48 h from 675:7 ^
269:7 to 383:6 ^ 123:9 (P , 0:0001), and by 60% from
553:5 ^ 261:9 to 232:2 ^ 153:4 ng/ml (P , 0:0001) 6
days postoperatively (Fig. 1).
The measured cytokine levels in patients treated with
MUF were also signi®cantly different postoperatively. Inter-
leukin-6 levels decreased by 60% from mean 792:9 ^ 580:4
to 318:4 ^ 393:4 ng/l (P , 0:0018). After 48 h and 6 days
changes in IL-6 after MUF were noticeable, but not statis-
tically signi®cant. Similar results were found in IL-8 after
24 h (P , 0:0004) and in TNF-a after 24 h (P , 000:3)
without signi®cance after 48 h or 6 days (Fig. 2).
3.2. Modi®ed ultra®ltration in normothermic CPB
After normothermic CPB the reduction of adhesion mole-
cules with modi®ed ultra®ltration was still present, but not
as remarkable as in the hypothermic patient group. Soluble
E-selectin peaked after 24 h (mean 193 ^ 93 ng/ml) in the
patient group not undergoing MUF. The difference after 24
h in the patients with MUF was 35% (P , 0:007). No
signi®cant changes were seen after 48 h and 6 days. Soluble
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Fig. 1. Expression of sE-selectin and sICAM-1 after hypothermic CPB at
different time intervals (**P , 0:01).
Fig. 2. Expression of IL-6 and IL-8 after hypothermic CPB at different time
intervals (**P , 0:01).
ICAM-1 levels in patients with MUF and without MUF
differed between 5 and 10% (Fig. 3).
In line with adhesion molecules were the values for cyto-
kines which revealed a maximal reduction after MUF of
25% for IL-6 after 24 h (NS), 8% after 48 h (NS), and of
20% after 6 days (NS). IL-8 was lowered by 30% after 24 h,
however without being statistically signi®cant. The range of
reduction otherwise varied between 5 and 10% (Fig. 4).
Soluble IL-2 receptor has neither in the normothermic,
nor in the hypothermic group effectively been removed from
the circulation (data not shown).
All clinical variables showed no signi®cant differences
between patients with or without MUF (Table 1).
4. Discussion
This study has demonstrated that surgery with cardiopul-
monary bypass is correlated with a signi®cant increase of
soluble adhesion molecules and cytokines in the serum
compared to preoperative levels. As we have shown in a
previous study [8] we found that hypothermia in CPB repre-
sents a much stronger stimulus to endothelial cells which
subsequently leads to signi®cantly higher levels of adhesion
molecules as well as cytokines levels compared to
normothermia. Modi®ed ultra®ltration after CPB in adult
patients undergoing coronary artery bypass grafting is an
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Fig. 3. Expression of sE-selectin and sICAM-1 after normothermic CPB at
different time intervals (**P , 0:01). Fig. 4. Expression of IL-6 and IL-8 after normothermic CPB at different
time intervals.
Table 1
Postoperative clinical variables in normothermic and hypothermic bypass with or without MUFa
Normothermic CPB Hypothermic CPB
MUF (n  30) No MUF (n  20) P, MUF (n  30) No MUF (n  17) P,
PAaO2 301.3 ^ 116.6 286.6 ^ 138.2 NS 308.4 ^ 115.7 364.0 ^ 137.1 NS
Blood loss (ml) 1100 ^ 400 1130 ^ 250 NS 1140 ^ 370 1450 ^ 633 NS
Transfusion (unit) 1.2 ^ 1.1 1.4 ^ 1.3 NS 1.4 ^ 1.5 1.5 ^ 1.1 NS
Temp max (C) 38.0 ^ 0.6 37.9 ^ 0.7 NS 38.0 ^ 0.5 38.1 ^ 0.6 NS
Lc max (£1000) 11.2 ^ 3.1 10.2 ^ 4.0 NS 11.4 ^ 2.5 11.8 ^ 3.0 NS
CRP max 164 ^ 58 133 ^ 36 NS 189 ^ 81 166 ^ 55 NS
Inotropic support (n) 13 10 NS 15 12 NS
Atrial ®brillation (n) 15 9 NS 15 8 NS
Pulmonary infection (n) 8 3 NS 4 7 NS
Intubation (days) 13.3 ^ 5.8 14.0 ^ 3.4 NS 17.5 ^ 11.5 15.9 ^ 5.8 NS
ICU stay (days) 2.0 ^ 1.9 2.2 ^ 3.3 NS 2.4 ^ 1.9 2.4 ^ 2.3 NS
Hospital stay (days) 11.0 ^ 2.1 10.4 ^ 4.3 NS 9.5 ^ 2.9 10.8 ^ 4.0 NS
a PAaO2, pulmonary-alveolar O2-gradient; Lc, leukocyte; CRP, C reactive protein; NS, not signi®cant.
effective tool to signi®cantly lower adhesion molecules and
cytokines from the blood immediately after termination of
cardiopulmonary bypass.
The release of proin¯ammatory cytokines (TNF-a , IL-6,
IL-8, IL-2R), as well as upregulation of adhesion molecules
may play a vital role in the whole body in¯ammatory
response encountered after cardiopulmonary bypass. Ultra-
®ltration has been proposed to be a way to reduce at least
some of the in¯ammatory mediators as well as the amount
of accumulated tissue water generated during pediatric
cardiac surgery [9±11]. Hemo®ltration also showed to be
effective in controlling water balance, concentration of clot-
ting factors and improved early postoperative PaO2 and time
of extubation as well as postoperative blood loss [12].
However, there has been no report to date of a prospective
randomized study in an adult patient population demonstrat-
ing a signi®cant impact in lowering adhesion molecules and
cytokines after CPB as well as its correlation to clinical
outcome.
Casey et al. studied the adverse effects of experimental
cytokine administration and the prognosis related to high
plasma concentrations of cytokines in sepsis [13]. However,
the clinical bene®t of cytokine neutralization or removal has
not been proven. In addition, other studies suggest that
plasma cytokine concentrations are only circulating markers
of an in¯ammatory process occurring at tissue level [14].
Tumor necrosis factor alpha (molecular weight 17±50
kDa) was one of the ®rst cytokines to be implicated in the
activation of endothelial cells, causing hypotension and
leukopenia. IL-6 (molecular weight 20±30 kDa) is produced
via in¯ammatory response including a protease-mediated
pathway from myocardium during postischemic reperfusion
in patients undergoing coronary artery bypass grafting [15].
In myocardial infarction serum level of IL-6 are signi®-
cantly elevated [16] and IL-6 mRNA are expressed in the
area of infarcted myocardium or in hypoxic neonatal
myocytes [17]. The production of IL-8 (molecular weight
8±10 kDa) during CPB has been described in several studies
[18]. This cytokine has been shown to be a most powerful
neutrophil and T-lymphocyte chemotactic factor. It has also
been found to stimulate neutrophil adherence to endothelial
cells and extracellular matrix proteins [19]. It has been
demonstrated that IL-8 plays a role of in the pathogenesis
of adult respiratory distress syndrome, which has also been
reported as a complication of postbypass surgery [18].
Although our results clearly demonstrate that modi®ed
ultra®ltration signi®cantly lowers adhesion molecules and
cytokines after CPB, we were unable to detect any signi®-
cant impact of MUF in all clinical variables studied or in the
patients outcome. Ultra®ltrated patients showed less blood
loss within 24 h and subsequently less transfusion had to be
given compared to the patients not treated with MUF. A
reduction in postoperative bleeding by MUF was reported
by Naik and colleagues. They speculated that the effect of
hemoconcentration itself and increased concentration of
clotting factors, including platelets, after MUF lead to
improved coagulation [7]. Probably the most changes post-
operatively was seen in the improvement in postoperative
PaO2 and the reduction in duration of mechanical ventila-
tion. However, no difference between the groups was
observed regarding the duration of ICU stay or hospital
stay. The slight increase in the neutrophil count seen in
the hypothermic patients postoperatively compared to the
normothermic patients may be due to circulating C3a and
C5a promoting release of leukocytes and precursors from
bone marrow [20]. Our ®ndings of increased adhesion mole-
cules and cytokines in the hypothermia group may in part be
explained by a higher leukocyte count and therefore stron-
ger in¯ammatory response. Royston and coworkers
observed that up to 50% of circulating polymorphonuclear
leukocytes are selectively trapped in the pulmonary capil-
laries during the rewarming period, with subsequent degra-
nulation of additional in¯ammatory mediators contributing
to endothelial damage [21]. However, not only pro-in¯am-
matory but also anti-in¯ammatory cytokines are released
during cardiopulmonary bypass, which may play a protec-
tive role by actually suppressing the production of pro-
in¯ammatory mediators. IL-10 is a potent inhibitor of the
production of TNF-a , as well as IL-1b, IL-6, and IL-8 [22].
This cytokine is produced during septicemia and exerts a
protective role while down-regulating TNF-a production in
tissue macrophages [23]. Its neutralization or removal from
the circulation through MUF may therefore theoretically be
deleterious. More apparent disadvantages in performing
modi®ed ultra®ltration after terminating cardiopulmonary
bypass are that decannulation is delayed for about 15 min,
and there is also a potential danger of hypotension caused by
excessive rate of ultra®ltration jeopardizing adequate coron-
ary blood ¯ow and myocardial perfusion. Also, exposure of
blood to ®lter and its connecting circuit might theoretically
increase the in¯ammatory stimuli and potentiate comple-
ment activation and cytokine release during the use of
hemo®ltration. However, no studies showed any additional
increase in complement activation during the procedure of
ultra®ltration itself [12] as long as no ®lter which contain
nylon are used.
As we already pointed out [8] adhesion molecule and
cytokine levels were signi®cantly elevated in patients after
hypothermic cardiopulmonary bypass compared to patients
operated on under normothermic conditions. Interestingly,
MUF turned out to be signi®cantly more effective in the
hypothermia group lowering cytokine levels up to 60%
and adhesion molecules up to 37% after 24 h. Under
normothermic conditions the reduction through MUF was
minimal showing only a signi®cant decrease in sE-selectin
levels after 24 h while all other parameters were almost
unchanged. However, no signi®cant differences have been
seen after MUF between normothermia and hypothermia. A
possible explanation for this ®nding is the fact, that since the
amount of circulating adhesion molecules and cytokines
released after hypothermic CPB exceeds signi®cantly the
amount after normothermic CPB, obviously more mole-
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cules get removed in a given time. The ultra®lter used in our
study, apparently, was able to remove adhesion molecules
and cytokines from the circulation to a certain degree
regardless of how high the levels were to begin with. To
prove the ef®cacy of the ®lter we also analyzed the ultra®l-
trate, in which showed almost identical levels pre-ultra®l-
tration and in the ultra®ltrate. The fact, that sIL-2R with a
molecular weight of 40±50 kDa was not removed from the
circulation by MUF, couldn't be explained by different
molecular weights. We believe that different conformations
of molecules might contribute to the ef®ciency of the ultra-
®lter to remove the substances in the plasma. This ®nding,
however, is in line with other reports of patients in which the
usually high sIL-2R levels in renal failure were unaffected
by dialysis [24]. Therefore, any possible adverse effects of
IL-2 secretion by activated T-cells cannot be altered by
MUF.
Modi®ed ultra®ltration has shown to be ef®cient not only
in removing soluble in¯ammatory mediators from the circu-
lation, but also may indeed have an impact on clinical vari-
ables (i.e. hemostasis, PAaO2) in children. We agree with
Ramamoorthy and colleagues on their comment that we
now do need to focus on clinical outcome measures, rather
than the assay of cytokines [25]. Current evidence suggests,
that MUF is an ef®cient way of removing in¯ammatory
mediators and helping blood conservation, probably best
suited to the pediatric patient population in whom blood
loss and transfusion requirements are signi®cant. However,
our study failed to demonstrate any signi®cant clinical bene-
®t in adults after elective coronary artery bypass surgery
except for better DAaO2 values and slightly earlier extuba-
tion. Taking into account all advantages and disadvantages,
we believe, that modi®ed ultra®ltration might be more bene-
®cial in patients with cardiogenic shock undergoing emer-
gent cardiac operation and with a presumably longer
postoperative course.
In conclusion, modi®ed ultra®ltration is able to lower
adhesion molecules and cytokine levels signi®cantly after
elective coronary artery bypass surgery in adults, although
its role in reducing postoperative morbidity and increasing
outcome is yet to be shown.
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Appendix A. Conference discussion
Dr J. Fragata (Lisbon, Portugal): We have used modi®ed ultra®ltration
in around 100 patients after coronary artery bypass grafting, and what we
noticed is that there is a marked clinical bene®t, as expressed by less blood
use, less bleeding, and less time on the ventilator. I wonder, and you haven't
mentioned in your study, whether your results were due only to the increase
in hematocrit because of the ®ltration. We think there is more than that,
because you also remove in¯ammatory mediators. Could you please
compare the hematocrits you achieved with both methods that you used,
and, second, did you measure the concentration of in¯ammatory mediators
in the ultra®ltrate?
Dr GruÈnenfelder: To the ®rst question, the hematocrits changed. We
did not actually look at that speci®cally, because, as you know, if you
transfuse blood into a patient, usually, and that has been reported in several
studies, interleukin-8 and -6 will be transfused as well. We actually did not
have any speci®c data about when we have to transfuse, since the patients in
the ICU will be treated in our institution by anesthesiologists. So we have
no access exactly how to and when to transfuse.
Dr Fragata: The point I was trying to raise is that we can, of course, get
rid of extra ¯uid just by giving a diuretic such as furosemide, but the clinical
effect we get with modi®ed ultra®ltration is different and more intense,
when compared to the same amount of ¯uid you lose just by using a
diuretic. So I think this method is very advantageous, and actually in our
series that we are about to publish, we could clearly demonstrate the clinical
bene®t, expressed by less bleeding and transfusion and less time on the
ventilator. The other point is, could you analyze what you were actually
draining out in the ultra®ltrate?
Dr GruÈnenfelder: Yes. We speci®cally looked at the ultra®ltrate, too,
and it showed that the amount of cytokines in the ultra®ltrate actually
represents the same amount preultra®ltration. So we actually ®ltered the
same amount out of the circulation as the amount of circulating proin¯am-
matory mediators in the circulation before ®ltration.
Dr S. Wan (Hong Kong, China): How did you determine your sampling
points? The current sampling points just exactly missed the peak release of
those cytokines, especially TNF and interleukin-8.
Dr GruÈnenfelder: That may be correct for the cytokines, but from
previous studies done at our institution, we know that speci®cally the adhe-
sion molecules peak not before 12 h, and we have performed studies to
con®rm that, and we showed that the peak for E-selectin and ICAM-1 is at
18±24 h. It's true that the cytokines peak before that. But we think for that
reason that we have a correlation to the adhesion molecules that wouldn't
matter too much.
Dr Wan: In that case, how can you determine that reduced adhesion
molecule is due to ultra®ltration and not relates to the other post-operative
treatments?
Dr GruÈnenfelder: We think that since we are ®ltrating cytokines also,
the stimulus after transporting the patient to the ICU is reduced. Since we
found adhesion molecules in the ultra®ltrate, we know that we also ®lter
adhesion molecules, although the peak of adhesion molecules is at 24 h.
Dr A.M. El Gamel (London, UK): You cannot extrapolate a lot out of
your result because the number of your patients is so small and you cannot
say the ultra®lter doesn't help. You need a large number of patients to prove
the clinical value of it. Although the cytokine results are quite clear, you
take the proin¯ammatory cytokines out, and I am just wondering before we
make a clinical statement on the value of ultra®ltration, we have to continue
to evaluate it.
Dr GruÈnenfelder: That's correct.
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